• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OneMedNet Announces CEO Succession Plan

    4/2/24 4:05:00 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ONMD alert in real time by email

    ~ President, Aaron Green, Assumes Role of Chief Executive Officer ~

    ~ CEO, Paul Casey, Announces Retirement and Shift to Active Advisory Role to Guide Transition Successfully ~

    ~ Casey to Remain on Board Post-Transition ~

    President and Chief Executive Officer

    MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), the leading curator of regulatory-grade imaging Real World Data ("iRWD™"), today announced that its President, Aaron Green, has assumed the role of President and Chief Executive Officer, in addition to an appointment to OneMedNet's Board of Directors. Mr. Green will succeed CEO, Paul Casey, who has announced his retirement and who will continue to serve on the Board of Directors.

    Mr. Green is a seasoned public company executive and healthcare IT leader, with more than 20 years of experience including an impressive track record of driving growth, leading business transformations and creating shareholder value. As President and CEO, Green will lead all facets of OneMedNet's business involving its iRWD™ offering, including R&D, product, strategy, and sales across global markets. Under Mr. Green's leadership, the Company has successfully added four new large strategic partners which nearly doubles OneMedNet's clinical data Network in 2024 to-date, and has already contributed to growth in bookings of 15% year-over-year.

    Prior to joining OneMedNet, Green served as General Manager Radiology Imaging at Change Healthcare, and most recently as Vice President Cloud Solutions, at Optum Insights, where he was responsible for developing and exceeding the P&L, Bookings, Revenue and EBITDA targets of its Cloud Solution lines. Prior to Change Healthcare, he spent 15 years at McKesson growing to Division Vice President, Sales where he led executives, salespersons and staff across the US, Canada, and the US-government territories.

    Paul Casey, commented, "Upon accepting the role of CEO in 2022, my goal was to properly position the Company for public life, and we've successfully completed this milestone with our IPO in November 2023. Aaron's past successes as a business leader within the healthcare IT industry and necessary relevant public company experience made him the perfect candidate to assume the CEO role upon my retirement. Since Aaron joined, I have confidence that Aaron's many years of successful executive leadership coupled with the depth of his direct industry expertise offered the necessary talent to drive OneMedNet forward. Having worked daily with Aaron since he assumed the role of President, the time is right for us to complete this leadership transition. OneMedNet could not be in better hands, and I look forward to working with Aaron to ensure a smooth and more importantly, successful transition. It is my privilege to hand over the reins to Aaron."

    "I am honored to be named, and eager to assume the CEO position here at OneMedNet," commented Green. "I would like to thank Paul for demonstrating solid leadership through OneMedNet's structural shift and the mentorship he has provided to not only myself but the entire OneMedNet team. I would also like to thank the Board of Directors for placing its trust in me to serve as the next CEO of OneMedNet."

    "Paul's leadership and commitment to OneMedNet, our employees and our investors has been invaluable. On behalf of the entire OMN team, I want to thank Paul for the tremendous impact he has had on our team and business during his time with the Company, and I look forward to continuing to work closely with Paul and appreciate the important role he'll play in setting his successor up for success," said Dr. Jeffrey Yu, OneMedNet's Founder Chief Medical Officer, and Chairman.

    "The CEO transition from Paul to Aaron is a direct reflection of the Board's mindful succession planning and our confidence that the Company will see continued operational momentum as Aaron assumes the role of CEO," added Dr. Jeffrey Yu. "Aaron embodies our values of quality and commitment to responsiveness in clinical imaging and curation of iRWD™ based upon success in compiling one of the largest networks of imaging centers, comprised of hospitals, imaging centers and clinics, throughout the United States, Canada, United Kingdom, and growing covering more than 47 million patients to date," concluded Dr. Yu.

    About OneMedNet Corporation 

    Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical data repositories of healthcare providers. OneMedNet's robust iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records (EHR), laboratory results, medical imaging data. Employing its proven OneMedNet iRWD™ platform, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to healthcare providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. Our commitment to leveraging real-world data translates into healthcare innovations, setting new standards in patient care and advancing the future of medicine. For more information, please visit www.onemednet.com.

    Investor Contacts:

    Shannon Devine / Rory Rumore

    MZ Group North America

    203-741-8811

    [email protected]

    Company Contact:

    OneMedNet Corporation

    Michael Wong, Director of Marketing

    Phone: 800-918-7189

    Email: [email protected] 

    Source: OneMedNet

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d23f0f75-babb-4511-8a38-c500711331b2



    Primary Logo

    Get the next $ONMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Green Aaron was granted 1,090,000 shares and converted options into 240,425 shares, increasing direct ownership by 222% to 1,930,425 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:54:53 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet Reports Strong Momentum and Industry Excitement at RSNA

    MINNEAPOLIS, Dec. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network, today announced significant engagement and growing commercial traction following a productive four days at the Radiological Society of North America (RSNA) Annual Meeting. Throughout the event, it was clear that hospitals, imaging centers, and life sciences innovators are eager to join the OneMedNet Network and utilize its updated iRWD™ platform, powered by Palantir Foundry. RSNA 2025 provided clear market validation for OneMedNet across provider and life sciences ecosystems, affirming t

    12/10/25 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet to Showcase Transformative New Platform at RSNA 2025

    MINNEAPOLIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), the curator and provider of the largest global live, regulatory-grade AI-ready Real-World Data (RWD) network today announced strong validation from customers and prospects on its completely redesigned data exploration and cohort-building platform at ISPOR Europe and will showcase this new platform at RSNA in Chicago.  Executives and scientific leaders from global pharmaceutical companies, contract research organization, and healthcare technology firms participated in live demonstrations at ISPOR. Feedback has been consistently positive of the new user interface and its advanced discovery capabilities, unde

    11/24/25 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Accelerates Subscription Revenue Strategy with Industry-Leading Network Expansion: Clinical Exams Increase 37%, Patient Records Grow 38%

    MINNEAPOLIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), the curator and provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a significant network expansion that materially strengthens its position as one of the largest live Real-World Data networks in the world and supports the company's subscription offerings. In the three months since August 2025, OneMedNet has expanded its iRWD™ network as follows: Added approximately 380 provider sites → total now exceeding 2,130 (+22% network scale)Increased unique de-identified patient records by 13 million → total now exceeding 47 million (+38%)Expanded clinical exams and images by 50 million →

    11/20/25 9:00:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Casaburi Eric bought $39,262 worth of shares (20,475 units at $1.92) and was granted 90,000 shares (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:54:45 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by OneMedNet Corp

    SCHEDULE 13G/A - OneMedNet Corp (0001849380) (Subject)

    11/14/25 5:27:22 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 424B3 filed by OneMedNet Corp

    424B3 - OneMedNet Corp (0001849380) (Filer)

    11/14/25 5:26:23 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by OneMedNet Corp

    10-Q - OneMedNet Corp (0001849380) (Filer)

    11/14/25 4:31:20 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    3/3/25 8:35:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development

    MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We are thrilled to join forces with Bayer's AI Innovation Platform," said Aaron Green, CEO & President of OneMedNet. "This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare

    12/2/24 8:30:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet appoints new CFO

    MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golden has served as the Managing Partner of Cohen, Bender & Golden LLP since 2015, where he provides consulting, accounting and tax services to middle market businesses and owners. Mr. Golde

    9/10/24 8:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    11/12/24 3:35:37 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    10/1/24 5:01:18 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    8/5/24 5:15:39 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Financials

    Live finance-specific insights

    View All

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

    MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial Highlights Improved Balance Sheet: Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have been reduced from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, a reduction of approximately $13.5 million. Additional discounted debt settl

    8/14/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care